Key Takeaways

  • In SYNCHRONIZE-CVOT, a phase 3 trial of 5,530 adults with obesity at increased cardiovascular risk, the dual GLP-1/glucagon agonist survodutide met its primary endpoint.
  • Weight loss at week 72 reached 13.7% at the 6 mg dose versus 2.0% on placebo.
  • Gastrointestinal side effects were the main cost: about one in five participants on survodutide stopped treatment because of them, versus 1.9% on placebo.

The Question Was Not "Does It Work?" — It Was "Is It Safe for Hearts?"

Survodutide's biggest trial was not about weight. SYNCHRONIZE-CVOT, published Monday in The Lancet and presented at the American Heart Association's Scientific Sessions, enrolled 5,530 adults with obesity or overweight (BMI ≥27) who already had cardiovascular disease, chronic kidney disease, or multiple risk factors — and asked whether the weekly dual GLP-1/glucagon agonist is safe for their hearts.

The answer: yes, by the trial's terms. For the primary endpoint — a five-part composite of cardiovascular death, heart attack, stroke, coronary revascularisation and heart-failure events — survodutide met non-inferiority versus placebo (hazard ratio 0.89; 95% CI 0.67–1.18). Read that carefully: it proves no excess cardiovascular risk, not a cardiovascular benefit — the confidence interval crosses 1, so a protective effect is unproven. A narrower three-part MACE endpoint gave a hazard ratio of 0.84, also non-inferior.

The Weight Numbers, and the Dropout Numbers

Weight was a secondary endpoint: at week 72, participants lost up to 13.7% of body weight on survodutide versus 2.0% on placebo, alongside significant reductions in blood pressure, waist circumference, hs-CRP and triglycerides.

The honesty beat is tolerability. The most common side effects were gastrointestinal — nausea, vomiting, diarrhoea, constipation, mostly mild to moderate — but 19.3% of the 3.6 mg group and 20.8% of the 6.0 mg group stopped treatment because of GI adverse events, versus 1.9% on placebo. Boehringer Ingelheim notes the dropouts clustered during dose escalation under a protocol with limited titration flexibility, and that follow-up studies use gentler schedules. Survodutide is not approved anywhere; Boehringer says it is preparing regulatory submissions in obesity, and it is also in phase 3 trials for the liver disease MASH.

Health note: this is a safety readout, not an availability announcement — survodutide cannot be prescribed, and anyone considering this class of medication should discuss established options with their own clinician.

The Twikup Take

Regulators learned the hard way to demand heart-safety data from weight drugs, and this is that homework handed in: the first dual agonist to clear a cardiovascular outcomes trial — with the dropout rate, not the hazard ratio, as the number patients will actually feel.

Image: Illustrative image.

Sources